Transplantation of organs is an important form of therapy for the treatment of end-stage kidney, liver and heart disease. Unfortunately, current clinical practice relies on potent, non-specific immunosuppressive drugs which are neither totally successful in preventing rejection nor free from complications. In order to develop more specific and effective therapies it is imperative that we improve our understanding of the process of allograft rejection and develop novel strategies for tolerance induction. The proposed research will develop and assess a non-myeloablative protocol to induce indefinite allograft survival and tolerance in a murine model and thus facilitate the rational application of such intervention to clinical transplantation. Our central hypothesis is that the combination of donor bone marrow transfusion and CTLA4-Ig treatment will provide a clinically relevant means to prolong allograft survival indefinitely and induce transplantation tolerance. We propose to test this hypothesis in the murine system because it provides both a vascularized cardiac allograft model in which to refine this treatment protocol and unique cellular and molecular tools to analyze the immunologic mechanisms. Specifically, in this model we will: (1) define the optimal protocol for the induction of donor specific transplantation tolerance using the combination of CTLA4- Ig and donor bone marrow transplant (BMT); (2) use molecular, immunohistological, and flow cytometric techniques to characterize the development and nature of hematopoietic chimerism in CTLA4-Ig/BMT transplant recipients; (3) define the role of hematopoietic chimerism in transplantation tolerance induced by CTLA4-Ig/BMT: (4) determine the critical cell population required for the prolongation of allograft survival using bone marrow transplants either deficient in or enriched for specific cell lineages; (5) test the efficacy of administering the critical cell population for the establishment of chimerism and transplantation tolerance; (6) analyze the specific alterations in the recipient T cell population which are associated with CTLA4-Ig/BMT induced tolerance. The development and mechanistic analysis of the optimal CTLA4-Ig/BMT protocol for tolerance induction in the murine model will allow this knowledge to be applied large animal transplant models to test the ability of CTLA4-Ig/BMT to prolong allograft survival prior to application to clinical transplantation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK050762-04
Application #
2882789
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1996-03-01
Project End
2000-02-29
Budget Start
1999-04-05
Budget End
2000-02-29
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Emory University
Department
Surgery
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Arbiser, Jack L; Bingaman, Adam; Durham, Megan et al. (2002) SVR angiosarcomas can be rejected by CD4 costimulation dependent and CD8 costimulation independent pathways. Mol Med 8:551-8
Bingaman, A W; Ha, J; Durham, M M et al. (2001) Analysis of the CD40 and CD28 pathways on alloimmune responses by CD4+ T cells in vivo. Transplantation 72:1286-92
Ha, J; Bingaman, A W; Durham, M M et al. (2001) Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway. Transpl Immunol 9:13-7
Baldwin 3rd, W M; Larsen, C P; Fairchild, R L (2001) Innate immune responses to transplants: a significant variable with cadaver donors. Immunity 14:369-76
Bingaman, A W; Ha, J; Waitze, S Y et al. (2000) Vigorous allograft rejection in the absence of danger. J Immunol 164:3065-71
Bingaman, A W; Pearson, T C; Larsen, C P (2000) The role of CD40L in T cell-dependent nitric oxide production by murine macrophages. Transpl Immunol 8:195-202
Bingaman, A W; Waitze, S Y; Alexander, D Z et al. (2000) Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning. Transplantation 69:2491-6
Durham, M M; Bingaman, A W; Adams, A B et al. (2000) Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 165:4-Jan
Niimi, M; Pearson, T C; Larsen, C P et al. (1998) The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol 161:5331-7
Elwood, E T; Larsen, C P; Cho, H R et al. (1998) Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 65:1422-8

Showing the most recent 10 out of 12 publications